The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques—implications for recombinant vaccine design

被引:0
作者
Philip A. Mudd
Shari M. Piaskowski
Patricia C. Costa Neves
Richard Rudersdorf
Holly L. Kolar
Christopher M. Eernisse
Kim L. Weisgrau
Marlon G. Veloso de Santana
Nancy A. Wilson
Myrna C. Bonaldo
Ricardo Galler
Eva G. Rakasz
David I. Watkins
机构
[1] University of Wisconsin-Madison,Department of Pathology and Laboratory Medicine
[2] Laboratório de Biologia Molecular de Flavivírus,Instituto de Tecnologia em Imunobiológicos
[3] Instituto Oswaldo Cruz-Fiocruz,Wisconsin National Primate Research Center
[4] Fundação Oswaldo Cruz,undefined
[5] University of Wisconsin-Madison,undefined
来源
Immunogenetics | 2010年 / 62卷
关键词
Yellow fever 17D; Vaccine; Cytotoxic T lymphocyte; Indian rhesus macaque;
D O I
暂无
中图分类号
学科分类号
摘要
The yellow fever vaccine 17D (YF17D) is one of the most effective vaccines. Its wide use and favorable safety profile make it a prime candidate for recombinant vaccines. It is believed that neutralizing antibodies account for a large measure of the protection afforded to YF17D-vaccinated individuals, however cytotoxic T lymphocyte (CTL) responses have been described in the setting of YF17D vaccination. YF17D is an ssRNA flavivirus that is translated as a full-length polyprotein, several domains of which pass into the lumen of the endoplasmic reticulum (ER). The processing and presentation machinery for MHC class I-restricted CTL responses favor cytoplasmic peptides that are transported into the ER by the transporter associated with antigen presentation proteins. In order to inform recombinant vaccine design, we sought to determine if YF17D-induced CTL responses preferentially targeted viral domains that remain within the cytoplasm. We performed whole YF17D proteome mapping of CTL responses in six Indian rhesus macaques vaccinated with YF17D using overlapping YF17D peptides. We found that the ER luminal E protein was the most immunogenic viral protein followed closely by the cytoplasmic NS3 and NS5 proteins. These results suggest that antigen processing and presentation in this model system is not preferentially affected by the subcellular location of the viral proteins that are the source of CTL epitopes. The data also suggest potential immunogenic regions of YF17D that could serve as the focus of recombinant T cell vaccine development.
引用
收藏
页码:593 / 600
页数:7
相关论文
共 214 条
  • [11] Keyserling HL(2004)Identification of seventeen new simian immunodeficiency virus-derived CD8+ T cell epitopes restricted by the high frequency molecule, Mamu-A*02, and potential escape from CTL recognition J Immunol 173 5064-2634
  • [12] Ploss A(2007)The antiviral efficacy of simian immunodeficiency virus-specific CD8+ T cells is unrelated to epitope specificity and is abrogated by viral escape J Virol 81 2624-298
  • [13] Rice CM(2007)Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus Trans R Soc Trop Med Hyg 101 289-9205
  • [14] Orenstein WA(2000)Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases J Virol 74 9197-5224
  • [15] Mulligan MJ(2005)A computational resource for the prediction of peptide binding to Indian rhesus macaque MHC class I molecules Vaccine 23 5212-900
  • [16] Ahmed R(1981)Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine Bull World Health Organ 59 895-394
  • [17] Bonaldo MC(2005)New developments in flavivirus vaccines with special attention to yellow fever Curr Opin Infect Dis 18 387-507
  • [18] Garratt RC(2008)Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes J Infect Dis 198 500-125
  • [19] Caufour PS(2009)Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans Nat Immunol 10 116-4652
  • [20] Freire MS(2010)Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Vaccine 28 4644-209